Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Enzon's PEG-SN38 Featured in Clinical Cancer Research
April 1st, 2008
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that PEG-SN38 is featured in the March 15th issue of Clinical Cancer Research published by the American Association for Cancer Research, Inc. (AACR). PEG-SN38, a PEGylated form of SN38, utililizes new releasable PEGylation technology developed at Enzon. The technology enabled significantly increased solubility, a longer apparent half-life, higher exposure, and significantly enhanced therapeutic index compared to CPT-11 in several preclinical xenograft models, including models of in vivo CPT-11 resistance. In an experiment using xenograft models for breast tumors, treatment with PEG-SN38 given below...
Source: Cancer Weekly (2008-04-01)
|
